






Adverse maternal and perinatal outcomes in women
with previous preeclampsia: a prospective study
Kate Bramham, MRCP; Annette L. Briley, MSc; Paul Seed, MSc; Lucilla Poston, PhD, FRCOG;
Andrew H. Shennan, PhD, FRCOG; Lucy C. Chappell, PhD, MRCOGOBJECTIVE: The purpose of this study was to assess recurrence rates
of preeclampsia and neonatal outcomes in women with a history of pre-
eclampsia that required preterm delivery.
STUDY DESIGN: Five hundred women with previous preeclampsia that
required delivery at37 weeks’ gestation were followed prospectively.
RESULTS: Preeclampsia reoccurred in 117 women (23%). Predictive
factors included black (odds ratio [OR], 2.29; 95% confidence interval
[CI], 1.16–4.53) or Asian (OR, 2.98; 95% CI, 1.33–6.59) ethnicity, en-
rollment systolic blood pressure of 130 mm Hg (OR, 2.89; 95% CI,
1.52–5.50), current antihypertensive use (OR, 6.39; 95% CI, 2.38–
17.16), and proteinuria of 2 on enrollment urinalysis (OR, 12.35;











recruited as part of a
doi: 10.1016/j.ajog.2011.02.014
512.e1 American Journal of Obstetrics& Gynecology JUNE 201195% CI, 3.45–44.21). Women who previously delivered at 34
weeks’ gestation were more likely to deliver preterm again (29% vs
17%; relative risk, 1.69; 95% CI, 1.19–2.40) than were those women
with previous delivery between 34 and 37 weeks’ gestation.
CONCLUSION: Although this study confirms that women with previous
preeclampsia that required early delivery are at high risk of the develop-
ment of preeclampsia, the study identifies risk factors for recurrence
and illustrates that women with previous preeclampsia are at greater
risk of adverse neonatal outcome.
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aPreeclampsia is a multisystem disor-der that complicates approximately
4-6% of pregnancies in the United King-
dom1 and is associated with maternal
nd fetal death and morbidity. Women
ith a history of preeclampsia have a
igher risk of the development of pre-
clampsia in subsequent pregnancies,2-7
but the likelihoodor recurrence is poorly
defined; previous studies have either in-
cluded a majority of women who deliv-
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the risk of recurrence is low8 or have re-
lied on information that was drawn from
routinely collected clinical data in which
the accuracy of diagnosis may be impre-
cise.9 Women with previous preeclamp-
ia that required delivery at 34 weeks’
estation are of particular concern be-
ause it is recognized that they are at
reater risk of recurrent disease and
orse fetal outcome. The risk of the de-
elopment of preeclampsia in these
omen is also uncertain because pre-
ious reports have been of atypical
opulations and/ or small numbers of
omen.7,10
Recurrent preeclampsia has also been
associated with increased rates of preterm
delivery, delivery of a small-for-gesta-
tional-age (SGA) infant, and perinatal
death in women with recurrent pre-
eclampsia when compared with pre-
eclampsia in a first pregnancy.3,10 Al-
thoughahigher rate of associatedneonatal
complications might be anticipated, this
has not been investigated formally.
In this study, we report the results of a
planned secondary analysis of women
with a history of preeclampsia who wereprospective ran- cdomized control trial of vitamin C and E
supplementation in women who were at
increased risk of preeclampsia, forwhom
previous preeclampsia (delivery at 37
weeks’ gestation) was 1 of 8 entry crite-
ria.11 The objectives of this analysis were
to determine the incidence of recurrent
disease in women with previous pre-
eclampsia and to identify predictive risk
factors for subsequent preeclampsia. A
further objective was to define the neo-
natal outcome in those who did and did
not experience recurrent disease, in par-
ticular for those who previously deliv-
ered at34 weeks’ gestation.
MATERIALS AND METHODS
A randomized placebo controlled trial of
vitamin C and E supplementation (the
Vitamins in Preeclampsia trial, VIP no.
ISRCTN 62368611) was completed be-
tween August 2003 and June 2005.11 All
404 women who were recruited were
onsidered to be at increased risk for the
evelopment of preeclampsia according
o at least 1 of 8 defined criteria (Figure).
hey included 500 women with single-
on pregnancies who had preeclampsia





























































www.AJOG.org Obstetrics ResearchAfter recruitment at 140-216 weeks’
estation, women were assigned ran-
omly to receive placebo preparations or
000mg vitaminC and 400 IU vitamin E
aily until delivery. There was no signif-
cant difference in the primary outcome
f preeclampsia between women who
eceived placebo or treatment. In sub-
roup analyses of women with previ-
us preeclampsia, there were no sig-
ificant differences in preeclampsia,
ow birthweight, or SGA infants in the
ontrol and intervention arms; conse-
uently, data for women in the placebo
nd intervention arms were analyzed
ogether. Trial participants with mul-
iple pregnancies were excluded from
FIGURE
Inclusion criteria for vitamins in pr
Inclusion crit
 Previous preeclampsia immediately p
before 37 completed weeks’ gestation
 Diagnosis of HELLP syndrome (hemo
in any previous pregnancy at any stag
 Eclampsia in any previous pregnancy 
 Essential hypertension requiring medi
 Maternal diastolic blood pressure of 9
the current pregnancy 
 Type 1 or Type 2 diabetes requiring 
current pregnancy 
 Antiphospholipid antibody syndrome 
 Multiple pregnancy 
 Abnormal uterine artery Doppler wave
>0.67 or pulsatility index >1.65 with o
diastolic notches) 
 Primiparity with a body mass index (B
more
 
Bramham. Obstetric outcomes with previous preeclampsia. Ahe analysis.Personal and demographic details,
hich were obtained at the enrollment
isit, and pregnancy outcome were re-
orded in a customized secure password-
rotected internet-based study-specific
atabase. Urinalysis was confirmed by a
outine visual dipstick from amidstream
rine sample that was collected by clini-
al midwives.
The South East Multi Ethics Research
ommittee provided ethics approval
no. 00/01/027), and site-specific ap-
roval was obtained from all participat-
ng centers.
Definitions
Inclusion criteria for this analysis were
lampsia trial
 for VIP trial 
ding the index pregnancy, requiring delivery 
is, elevated liver enzymes, and low platelets) 
f gestation 
ny stage of gestation 
on, currently or previously 
m Hg or more before 20 weeks’ gestation in 
lin or oral hypoglycemic agents before the 
m (18-22 weeks’ gestation, mean resistance 
ithout the presence of unilateral or bilateral  
 at first antenatal appointment of 30 kg/m2 or 
Obstet Gynecol 2011.previous preeclampsia that was defined
JUNE 2011 Americs preeclampsia in the pregnancy pre-
eding the index pregnancy that re-
uired delivery at37 completed weeks’
estation. Chronic hypertension was de-
ned as a diastolic blood pressure of90
mHg (Korotkoff Stage 5) at the enroll-
ent visit or at20 weeks’ gestation or
he use of current or previous antihyper-
ensive medication. For women with
hronic hypertension and no protein-
ria, a diagnosis of preeclampsia was
efined as the new development of pro-
einuria in accordance with the Interna-
ional Society of Study of Hypertension
n Pregnancy (ISSHP) guidelines.12 In
women with preexisting proteinuria or
hypertension, a diagnosis of preeclamp-
sia was based on the development of ges-
tational hypertension or proteinuria or
after the identification of clinical or bio-
chemical markers or at least 1 additional
feature of preeclampsia (eg, HELLP [he-
molysis, elevated liver enzymes, low
platelets] syndrome or eclampsia). In
women with both essential hypertension
and preexisting proteinuria, the diagno-
sis was confirmed by 2 senior clinical
staff members who acted independently
who sought additional features of pre-
eclampsia, as outlined in the ISSHP
guidelines.12 Severe preeclampsiawas de-
ned according to ISSHP guidelines as
iastolic blood pressure of110mmHg
ith proteinuria as defined earlier.
Birthweights were assessed by cus-
omized birthweight percentile charts
www.gestation.net/birthweight_centiles/
entile_online.htm); SGA was consid-
red to be10th percentile. The follow-
ng available data were also used in anal-
sis: preterm birth (37 and34 weeks’
estation, both spontaneous and iatro-
enic), gestational age at delivery, peri-
atal death (intrauterine death at 24
eeks’ gestation or postnatal by 7 days),
ntenatal inpatient nights and mode of
elivery, and admission to neonatal unit.
Statistical analysis
Categoric variables were summarized
with the use of percentages and com-
pared with the use of the 2 test. Risk
ratios with 95% confidence interval (CI)
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develop confidence intervals for the dif-
ference in the arithmetic mean for indi-
ces of health care resources (maternal
and neonatal inpatient stay). Risk factors
for continuous outcome were analyzed
by linear regressionwith robust standard
errors and for binary outcome by logistic
regression,which is expressed as odds ra-
tio (OR) with 95% CI. A probability
value of .05 was determined to be sta-
tistically significant. Analysis was con-
ducted with SPSS software (version 16;
SPSS Inc, Chicago, IL) and Stata soft-
ware (version 10.1; StataCorp, College
Station, TX).
RESULTS
Baseline demographics and manage-
ment characteristics are provided in Ta-
ble 1 for the 500 women with previous
preeclampsia, according to the develop-
ment of recurrent preeclampsia that oc-
curred in 117 women (23%). Table 2
gives a comparison ofmaternal and neo-
natal outcomes in women who had pre-
eclampsia in the index pregnancy and
those who did not. The one maternal
death occurred in a woman with chronic
hypertension and human immunodefi-
ciency virus who had recurrent pre-
eclampsia. The death was subsequent to
and unrelated to the pregnancy.
Predictors of recurrent preeclampsia
are shown in Table 3. Age, body mass
index, smoking history, gestation of de-
livery in previous pregnancy for pre-
eclampsia, chronic renal disease, an-
tiphospholipid syndrome, and diabetes
mellitus were not associated with in-
creased risk of recurrent disease. Only
women who required current hyperten-
sive treatment were at greater risk for re-
current disease, whereas those women
who previously required antihyperten-
sive treatment were not (OR, 1.28; 95%
CI, 0.77–2.14).
Of thewomenwho experienced recur-
rent preeclampsia, those with previous
delivery at 34 weeks’ gestation (n 
6) were more likely to deliver an SGA
nfant (n 54 [71%] vs 12 [29%];P
0001) and to develop gestational hyper-
ension earlier (n  34.4 [interquartileTABLE 1
Baseline demographics according to outcome
Characteristic
No preeclampsia
(n  383; 77%)
Preeclampsia
(n  117; 23%)
Maternal age, ya 31.1  5.5 31.9  5.4
..............................................................................................................................................................................................................................................




White 309 (81) 72 (61)
.....................................................................................................................................................................................................................................
Black 42 (11) 26 (22)c
.....................................................................................................................................................................................................................................
Asian 23 (6) 14 (12)d
.....................................................................................................................................................................................................................................
Other 9 (2) 5 (3)
..............................................................................................................................................................................................................................................
Smoking status, n (%)
.....................................................................................................................................................................................................................................
Never 228 (60) 80 (68)
.....................................................................................................................................................................................................................................
Current smoker (including occasional/
social smoker)
46 (12) 10 (9)
.....................................................................................................................................................................................................................................
Stopped before present pregnancy 82 (21) 21 (18)
.....................................................................................................................................................................................................................................
Stopped during present pregnancy 27 (7) 6 (5)
..............................................................................................................................................................................................................................................
Maternal weight, kga 28.0  6.1 27.9  5.6
..............................................................................................................................................................................................................................................
Body mass index, n (%)
.....................................................................................................................................................................................................................................
25 kg/m2 137 (36) 41 (35)
.....................................................................................................................................................................................................................................
25-30 kg/m2 122 (32) 43 (37)
.....................................................................................................................................................................................................................................
31-35 kg/m2 71 (18) 19 (16)
.....................................................................................................................................................................................................................................
35 kg/m2 53 (14) 14 (12)
..............................................................................................................................................................................................................................................
Maternal baseline systolic blood pressure,
mm Hga
121  15 127 14e
.....................................................................................................................................................................................................................................
130 mm Hg, n (%) 265 (69) 58 (50)
.....................................................................................................................................................................................................................................
130-139 mm Hg 64 (17) 31 (26)f
.....................................................................................................................................................................................................................................
140 mm Hg 54 (14) 28 (24)f
..............................................................................................................................................................................................................................................
Maternal baseline diastolic blood pressure,
mm Hg
73 (10) 77 (10)c
.....................................................................................................................................................................................................................................
80 mm Hg, n (%) 253 (66) 55 (47)
.....................................................................................................................................................................................................................................
80-89 mm Hg, n (%) 100 (26) 46 (39)c
.....................................................................................................................................................................................................................................




Normal/trace 365 (95) 96 (82)
.....................................................................................................................................................................................................................................
 13 (3) 9 (8)h
.....................................................................................................................................................................................................................................
   5 (1) 12 (10)e
..............................................................................................................................................................................................................................................
Additional risk factors at enrollment, n (%)i
.....................................................................................................................................................................................................................................
Previous HELLP (hemolysis, elevated
liver enzymes, low platelets) syndrome
40 (10) 6 (5)
.....................................................................................................................................................................................................................................
Previous eclampsia 28 (7) 5 (4)
.....................................................................................................................................................................................................................................
Diabetes mellitus 15 (4) 3 (3)
.....................................................................................................................................................................................................................................
Chronic kidney disease 3 (0.8) 4 (3.4)
.....................................................................................................................................................................................................................................
Antiphospholipid syndrome 6 (1.6) 1 (0.9)
.....................................................................................................................................................................................................................................
Chronic hypertension 112 (29) 49 (42)



































































www.AJOG.org Obstetrics Researchtile range, 34.6–38.3]; P  .028). than
ere those women who delivered from
4-37 weeks’ gestation (n  41) to have
reterm deliveries at 37 weeks’ gesta-
ion (n 54 [71%] vs 16 [39%]; P
001) and at 34 weeks’ gestation (n 
1 [41%] vs 5 [12%]; P .001).
Similar risk factors were associated
ith preterm delivery (black ethnicity
OR, 3.03; 95% CI, 1.76–5.22], Asian
thnicity [OR, 4.25; 95% CI, 2.00–
.02]), systolic blood pressure of 140
m Hg (OR, 2.41; 95% CI, 1.43–4.07),
iastolic blood pressure of 80-90mmHg
OR, 1.96; 95% CI, 1.25–3.07), and dia-
tolic blood pressure of 90 mm Hg
OR, 2.20; 95% CI, 1.13–4.30). Systolic
lood pressure of 140 mm Hg (OR,
.41; 95%CI, 1.43–4.07), diastolic blood
ressure of 80-90 mm Hg (OR, 2.47;
5%CI, 1.65–3.71), diastolic blood pres-
ure of90 mm Hg (OR, 2.60; 95% CI,
.39–4.87)were also risk factors for SGA
nfants.
Comparison of pregnancy outcome
or women with a previous delivery for
reeclampsia at 34 weeks’ gestation
nd 34-37 weeks’ gestation is shown in
able 4. For women with previous deliv-
ry at 34 weeks’ gestation who did
ot experience preeclampsia, the risk of
elivery of an SGA infant remained
























a Data are given as mean SD; b Data are given as median
f P .002; g P .009; h P .03; i Women with1 risk
Bramham. Obstetric outcomes with previous preeclampsiation in a previous pregnancy wereore likely to be taking prophylactic as-
irin (187/304 [61.5%] vs 66/196
33.7%]; P .0001) or to be on antihy-
ertensive therapy (55/304 [18.1%] vs
8/196 [9.2%]; P  .006) than were
omen who previously delivered at34
eeks’ gestation.
COMMENT
In this prospective investigation, women
with preeclampsia who delivered at37
weeks’ gestation in a previous pregnancy
had a 1 in 4 risk (23%) of recurrent dis-
ease. Women with chronic hypertension
comprised one-third of the women with
previous preeclampsia who were re-
cruited; this conferred significant addi-
tional risk. Adversematernal andperina-
tal outcomes occurred not only in
women who experienced preeclampsia
again but also in those women who did
not; preterm delivery and delivery of an
SGA infant (by customized percentile)
were higher than in the general popula-
tion in both groups but were also more
likely to occur in those women with re-
current disease than in those women
who did not experience preeclampsia.
Women with recurrent preeclampsia
also had longer maternal inpatient stays;
neonatal unit admission was also in-
creased compared with women who did
not have recurrent disease, which reflects
utcome (continued)
No preeclampsia
(n  383; 77%)
Preeclampsia
(n  117; 23%)
..................................................................................................................




41 (11) 32 (27)e
..................................................................................................................
67 (18) 25 (21)
..................................................................................................................
..................................................................................................................
46 (58) 53 (68)
..................................................................................................................
1 (0.3) 8 (6.8)e
..................................................................................................................
5 (1.3) 20 (17.1)e
..................................................................................................................
quartile range); c P .001; d P .008; e P .001;
r were included in each relevant risk category.
J Obstet Gynecol 2011.the economic burden of the disease.
JUNE 2011 AmericWomen who previously delivered at
34 weeks’ gestation or from 34-37
weeks had similar rates of recurrence;
women in the former group were more
likely to have pretermdeliveries and SGA
infants.
Previous studies already have identi-
fied the low risk of recurrence in women
with delivery at term in the previous af-
fected pregnancy8; our trial focused on
he clinically more important cohort of
omen with previous preterm delivery
or whom risk of recurrence with associ-
ted adverse perinatal outcomes was
ikely to be high and who were relatively
nderrepresented in other studies.
Women with previous preeclampsia
ho had been recruited to 2 comparable
tudies of antioxidants for the preven-
ion of preeclampsia, which included
omenwith preeclampsia at37weeks’
estation, have reported similar risk
33%) or even higher risk (75% in de-
eloping countries) of recurrent dis-
ase.13,14 The recurrence rate in our
tudy of 25% for women who previ-
usly had delivered at34 weeks’ ges-
ation is also similar to that from a
uch smaller study of 120 women that
ncluded women with severe preterm
reeclampsia.7
Previous studies, which include women
with previous preeclampsia at any gesta-
tion, have either drawn on epidemio-
logic databases or are smaller cohort
studies. Two recent studies in large pop-
ulation databases report a recurrence
risk of 14% (19,960 women in Norway)4
and 15% (19,540 women in Sweden)15
but have limitations in the use of coded
diagnoses of uncertain validity and un-
known gestation of delivery in the previ-
ous pregnancy. Two cohort studies, in
which a more accurate diagnosis of pre-
eclampsia was made but without knowl-
edge of the gestation of previous pre-
eclampsia also report a lower recurrence
risk (15% and 18%).2,3,7,14 Preeclampsia
ost commonly occurs at term; there-
ore, all 4 studies are likely to include a
ajority of women who experienced
reeclampsia in the index pregnancy at
37 weeks’ gestation, which is associ-
ted with a lower risk of recurrence8 and




















Research Obstetrics www.AJOG.orgIn one study of Australian women in
which the definition of preeclampsia did
not require proteinuria, Brown et al6 re-
ported that women with nonproteinuric
preeclampsia in their first pregnancy
were more likely to experience nonpro-
teinuric preeclampsia in their next preg-
nancy and that the recurrence rate was
higher than amongwomenwithprotein-
uric preeclampsia in their first preg-
nancy. This highlights how variation in
the definition of preeclampsia can also
confound an accurate assessment of re-
TABLE 2
Maternal and neonatal outcome of






HELLP (hemolysis, elevated liver enzymes
..........................................................................................................
Antepartum hemorrhage, n (%)
..........................................................................................................
Spontaneous vaginal delivery, n (%)
..........................................................................................................
Instrumental delivery, n (%)
..........................................................................................................




















Preterm birth: 34 weeks’ gestation, n (%
..........................................................................................................
Perinatal death, n (%)
..........................................................................................................
Admission to neonatal unit or special care
..........................................................................................................
Inpatient stay in neonatal unit or special c
..........................................................................................................











a Data are given as mean SD; b Mean difference; confiden
d P .001.
Bramham. Obstetric outcomes with previous preeclampsicurrence rates;manywomen in the stud- m
512.e5 American Journal of Obstetrics& Gynecoloies referred to earlier would not have
been diagnosed with preeclampsia be-
cause of the requirement of proteinuria.
Moreover, cohorts have often been re-
cruited fromhomogeneous populations,
with underlying medical disorders ex-
cluded, with varying degree. Severity of
preeclampsia (other than gestation of
delivery) in an index pregnancymay also
contribute to recurrence risk8; however,
his usually relies on self-report and is
ifficult to define with accuracy.
Ethnicity may be an important deter-
men with recurrent preeclampsia
rrent pregnancy
Preeclampsia



































by unit, n (%) 49 (42)
.........................................................................................................................











tervals calculated by bias-corrected random bootstrap, with 10,0
J Obstet Gynecol 2011.inant. Most previous reports that have (
gy JUNE 2011ddressed recurrence of preeclampsia
ave included almost exclusively white
opulations.4-6 In our study, black and
Asian ethnicities were the only demo-
graphic predictor of recurrent pre-
eclampsia. Black ethnicity has also been
identified as a risk factor in women with
early-onset recurrent preeclampsia in
one other study.10 High rates of recur-
rent disease were reported in Brazilian
women of mainly nonwhite ethnicity
(37% recurrence)13 and in women from
ndia, Peru, South Africa, and Vietnam
No preeclampsia






1 (0.3) 9.82 (1.03–93.52)
..................................................................................................................
140 (37) 0.56 (0.38–0.82)
..................................................................................................................
33 (9) 0.50 (0.20–1.24)
..................................................................................................................
210 (55) 1.37 (1.19–1.58)
..................................................................................................................
156 (41) 1.64 (1.37–1.95)
..................................................................................................................
54 (14) 0.61 (0.32–1.15)
..................................................................................................................
5.06  6.56 5.91 (4.36–7.48)b
..................................................................................................................
2.07  5.85 7.91 (6.09–9.72)b
..................................................................................................................
2.99  2.27 1.99 (1.24–2.73)b
..................................................................................................................
..................................................................................................................
53 (43) 4.32 (3.23–5.78)
..................................................................................................................
14 (4) 0.75 (0.26–2.11)
..................................................................................................................
39 (39) 5.62 (4.02–7.87)
..................................................................................................................
22 (6) 3.39 (2.56–4.49)
..................................................................................................................
12 (3) 1.63 (0.63–4.27)
..................................................................................................................
40 (10) 4.01 (2.79–5.76)
..................................................................................................................
1.35  6.01 5.96 (1.55–6.37)b
..................................................................................................................
1 (0.2) 13.09 (1.48–116.0)
..................................................................................................................
..................................................................................................................





























































www.AJOG.org Obstetrics Researchthat ethnicity or factors that are rela-
ted to ethnicity (such as indices of depri-
vation) contribute to a high rate of
recurrence.
The population mix also represented
pregnant women with previous pre-
eclampsia in 25 centers across theUnited
Kingdom in whom comorbidities are
seen. These data are therefore generaliz-
able to populations with a similar repre-
sentation of other chronic diseases.
Chronic hypertension is an estab-
lished risk factor for preeclampsia. Up to
50% of pregnancies in women with se-
vere prepregnancy hypertension may be
complicated by preeclampsia.13,16,17 We
previously reported that 22% of women
with chronic hypertension experienced
preeclampsia.6 The difference in the re-
urrence rates between this and previous
TABLE 3








































Estimates were adjusted for age, maternal body mass index, e
blood pressure at booking, previous and current antihypertensiv
antiphospholipid syndrome, chronic kidney disease, and diabe
CI, confidence interval.
a P .016; b P .008; c P .001; d P .017; e P .00
Bramham. Obstetric outcomes with previous preeclampsitudies therefore may be determined in art by a high incidence of chronic hy-
ertension. Only women who require
ntihypertensive treatment at booking,
hichmay reflectmore severe hyperten-
ion, were at increased risk of having re-
urrent preeclampsia. Other prospective
tudies that reported high rates of recur-
ent preeclampsia also included a high
roportion of women with chronic hy-
ertension at study entry (24% and
1%).13 Reports that describe lower rates
f recurrent preeclampsia have low pro-
ortions of women with chronic hyper-
ension,5,18 or the incidence of chronic
ypertension is not reported.4
Women with chronic kidney disease
have elevated rates of preeclampsia and
superimposed preeclampsia, which in-
crease with severity of renal impair-
ment.19 Women with preeclampsia at
he recurrence of preeclampsia
tio

































ity, smoking, and maternal booking diastolic and systolic
rapy, and additional risk factors for trial entry that included
ellitus.
J Obstet Gynecol 2011.30 weeks’ gestation are more likely to
JUNE 2011 Americave underlying renal disease than those
ho experience preeclampsia later in
regnancy.20 In the present study, pro-
teinuria (2) at study entry was asso-
ciated strongly with recurrent superim-
posed preeclampsia.
Preeclampsia and fetal growth restric-
tion share underlying pathophysiologic
abnormalities that include defective pla-
centation because of inadequate tropho-
blast invasion, which results in reduced
placental blood flow and associated en-
dothelial dysfunction and angiogenic
factor disequilibrium. Fetal growth re-
striction in a first pregnancy, without
gestational hypertension, is also associ-
ated independently with hypertensive
disorders in the next pregnancy.21 It is
thus unsurprising that women with pre-
vious preeclampsia had a markedly in-
creased risk of an SGA infant than back-
ground; a novel aspect of our study is the
observation that delivery of an SGA in-
fant occurred in 56% of those pregnan-
cies with recurrent preeclampsia and
24% of subsequent pregnancies even
without recurrence. This is likely to re-
flect shared pathophysiologic condition
and the influence of other coexisting risk
factors (eg, chronic hypertension) and
may be the consequence of the inclusion
of a high proportion of women who de-
livered at 34 weeks’ gestation in their
previous pregnancy and the use of cus-
tomized percentiles that provide a more
accurate detection of important adverse
neonatal outcome.
Preterm delivery at 37 and 34
weeks’ gestation was elevated in women
with and without recurrent preeclamp-
sia compared with the general popula-
tion; however, rates were significantly
higher in women with recurrent pre-
eclampsia than in women without pre-
eclampsia and in womenwho previously
had delivered at 34 weeks’ gestation
than women who delivered later. The
majority of preterm deliveries were iat-
rogenic. In general, women with pre-
eclampsia that occurs at37 weeks’ ges-
tation have worse perinatal outcomes
than those who have preeclampsia at
term, with higher rates of perinatal mor-







































a. Amcental abruption.22 Several studies have
an Journal of Obstetrics& Gynecology 512.e6
Research Obstetrics www.AJOG.orgidentified previous preeclampsia as a sig-
nificant risk factor for preterm delivery
in future pregnancies and that these de-
liveries are predominantly because of
medical intervention.3,6,8,23-25 Dukler et
al also showed that severity of pre-
eclampsia in primiparous women was
correlated with preterm delivery in their
subsequent pregnancies.8
This study has a number of strengths;
it is one of the largest prospective analy-
ses of womenwith preeclampsia in a pre-
TABLE 4
Maternal and neonatal outcome of














HELLP (hemolysis, elevated liver enzymes






























Preterm birth: 34 weeks, n (%)
..........................................................................................................
5th birthweight percentile, n (%)
..........................................................................................................
Admission to neonatal unit/special care ba
..........................................................................................................
Inpatient stay in special care baby unit, da
...................................................................................................................
a Data are given as mean SD; b Mean difference; confiden
Bramham. Obstetric outcomes with previous preeclampsivious pregnancy that has used indepen-
512.e7 American Journal of Obstetrics& Gynecolodently confirmed diagnoses of recurrent
disease. The individualized and well-de-
fined diagnosis of preeclampsia without
reliance on hospital coding statistics,
which are known to be inaccurate, is an
important strength. Inclusion of a high
proportion of women with previous de-
livery at 34 weeks’ gestation is of par-
ticular value to clinicians because previ-
ous data are sparse. This multicenter
study from 25 units with a diverse spec-
trum with respect to age, ethnicity, body
men with early delivery for preeclam
r preeclampsia from 34-37 weeks’ g
Previous delivery for preecla

























7.5  7.9 6
.........................................................................................................................
3.8  6.7 2
.........................................................................................................................













unit, n (%) 70 (23) 19
.........................................................................................................................
6.0  17.8 9
.........................................................................................................................
tervals were calculated by bias-corrected random bootstrap, with
J Obstet Gynecol 2011.mass index, and additional risk factors
gy JUNE 2011enabled the results to be extrapolated to
the wider population.
Additionally, this is one of the first
studies to report pregnancy outcome in
women with previous preeclampsia to
have used customized birthweight per-
centiles to assess fetal growth restriction.
This enables distinction to be drawn be-
tween an infant being constitutionally
and pathologically SGA and provides
a better surrogate measure for fetal
growth restriction than standard growth
ia (<34 weeks’ gestation in last
tation in last pregnancy
sia
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www.AJOG.org Obstetrics ResearchThese data provide contemporaneous
and accurate figures that should be of
value in counseling women with previ-
ous preeclampsia that required delivery
at37weeks’ gestation and for guidance
in management strategies. These strate-
gies should focus on the identification of
risk that is based on demographic and
clinical factors at enrollment together
with existence of comorbidities and tar-
get appropriatemonitoring and prophy-
lactic therapies while acknowledging
that even those who do not develop re-
current preeclampsia may have a higher
than background risk of adverse out-
comes, such as SGA infants.
To date, no useful serologic predictors
of preeclampsia in womenwith previous
disease have been identified.13 We have
highlighted potentially important clini-
cal predictors of recurrent disease. Pro-
phylactic strategies should focus on
this group of women for secondary
prevention.
Aspirin is currently the only recom-
mended treatment to prevent the devel-
opment of the condition; however, out-
comes of those women with previous
preeclampsia that was treated and not
treated are varied.7 In this investigation,
ore women who had recurrent disease
ere taking aspirin for preeclampsia pre-
ention than those who did not; how-
ver, the effect of aspirin cannot be de-
ermined because of the uncontrolled
ature of prescribing (eg, women at
igher risk may have been more likely to
ave received aspirin). Furtherwork that
ill assess which subgroups of women
ould benefit from certain treatment
eg, aspirin) is necessary.
Long-term health risks in womenwith
reeclampsia are now well-recognized
nd include increased incidence of hy-
ertension, cardiovascular, cerebrovas-
ular, and renal disease.27-30 Women
ith recurrent preeclampsia in their sec-
nd pregnancies have been shown to
ave a significantly higher incidence of
hronic hypertension during a 10-year
ollow-up period than did women with
revious preeclampsia and normoten-
ive second pregnancies.31 The implica-
tions of recurrent preeclampsia for fu-
ture occurrence of other diseases that are
known to be more prevalent in womenwith previous preeclampsia (eg, cardio-
vascular disease) are unknown and re-
quire further study. f
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